TD Cowen on Vera Therapeutics (VERA): 'Launch prep remains on track; we have confidence in a clean approval'

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. APGE
6. DFTX
7. GOOGL
8. MU
9. IBM
10. HOOD

Go back to TD Cowen on Vera Therapeutics (VERA): 'Launch prep remains on track; we have confidence in a clean approval'

Wolfe Research: 'VERA's continued weakness is creating a favorable setup into the July 7th PDUFA'

June 2, 2026 12:28 PM EDT

Wolfe Research analyst Andy Chen reiterated an Outperform rating and $88.00 price target on Vera Therapeutics (NASDAQ: VERA)

The analyst comments "Fundamentally positive Vera for a few reasons (i) normally, Vera would need 96- week eGFR stabilization data to achieve full approval. In our view, this lowers the risk of eGFR failure, precluding the... More